Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Optical Coherence Tomography (OCT) Evaluation of Re-endothelization: A Comparison of the Intrepide™ Stent Versus Taxus™ (OISTER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00914420
Recruitment Status : Unknown
Verified April 2010 by Clearstream Technologies Ltd..
Recruitment status was:  Recruiting
First Posted : June 5, 2009
Last Update Posted : April 19, 2010
Information provided by:
Clearstream Technologies Ltd.

Brief Summary:

Patients presenting with ACS (Acute Coronary Syndrome) in the emergency department will be screened for clinical eligibility and asked to sign informed consent to the study.

A total of 40 patients will be randomized. 20 of them will receive a Trapidil eluting stent (Intrepide™ stent), 20 will receive a Paclitaxel eluting stent (Taxus™ stent). After 90 days the patients who were treated with the INTREPIDE stent in the first lesion will be treated with the Taxus stent in the second lesion. After 90 days the patients who were treated with the Taxus stent in the first lesion will be treated with the INTREPIDE stent in the second lesion.

Coronary angiography will be performed through the femoral (groin) or radial (wrist) artery with the use of standard techniques. The doctor will determine if the patient is qualified for enrolment at the end of the diagnostic coronary angiogram

Condition or disease Intervention/treatment Phase
Coronary Artery Disease Acute Coronary Syndrome Device: Intrepide Trapidil eluting stent Device: Taxus drug eluting stent Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: OCT Evaluation of Stent Struts Re-endothelization in Patients With Acute Coronary Syndromes: a Comparison of the Intrepide™ Stent vs. Taxus™
Study Start Date : June 2009
Estimated Primary Completion Date : November 2010
Estimated Study Completion Date : October 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Intrepide
Group A- Primary stenting with Intrepide trapidil eluting stent
Device: Intrepide Trapidil eluting stent

The INTREPIDE coronary stent system consists of a balloon expandable stent coated with two layers of Trapidil and parylene. The Trapidil eluting stent is pre-mounted on a Nimbus PCTA balloon and is intended for use in the treatment of CAD.

The controlled release of Trapidil is achieved through the parylene barrier, locally delivering the drug to the target lesion, inhibiting smooth muscle cell proliferation and hence neointimal hyperplasia.

Experimental: Taxus
Group B Stenting with Taxus DES
Device: Taxus drug eluting stent
Paclitaxel Drug eluting stent manufactured by Boston Scientific

Primary Outcome Measures :
  1. To compare stent re-endothelialization using Trapidil drug eluting stent versus Taxus paclitaxel eluting stent at 3 months after intervention. The primary endpoint will be defined by % of stent struts neointimal coverage at 90 days [ Time Frame: 3 months ]

Secondary Outcome Measures :
  1. In-stent binary angiographic restenosis and in-stent late lumen loss; in segment late loss; assessed by quantitative computed angiography (QCA) at 12 months [ Time Frame: 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:


  • >18 years of age,
  • symptoms of non ST-elevation ACS (defined by the ACC/AHA criteria) for 30 min but <48 h
  • Patient must provide written informed consent prior to the procedure using a form that is approved by the local Institutional Review Board


  • reference vessel diameter of culprit/target lesion between 2.25 to 3.5 mm (visual estimate)
  • discrete target lesion (maximum length of 28 mm by visual estimation)
  • target lesion is in a native coronary artery
  • presence of another lesion more than 70% in a vessel different from the culprit one amenable of planned percutaneous treatment 90 days thereafter.

Exclusion Criteria:


  • previously documented left ventricular ejection fraction of less than 30%
  • estimated life expectancy of less than 12 months
  • a history of bleeding diathesis, leukopenia, thrombocytopenia, or severe hepatic or renal dysfunction
  • participation in another study
  • inability to give informed consent owing to prolonged cardiopulmonary resuscitation
  • and dominant Renal impairment (serum creatinine > 2.0 mg/dl) Angiographic
  • non-culprit lesion located in the proximal LAD or in a proximal and dominant Circumflex artery
  • previous PCI of the target vessels restenosis or stent thrombosis as culprit lesion
  • unprotected left main coronary artery disease
  • non-culprit lesion located in a vein graft
  • severe multivessel disease (three major epicardial vessel disease) need of overlapping stenting for one lesion

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00914420

Layout table for location information
University Hospital Modena Recruiting
Modena, Italy
Contact: Giuseppe M Sangiorgi, MD   
Principal Investigator: Giuseppe Sangiorgi, MD         
Sponsors and Collaborators
Clearstream Technologies Ltd.
Layout table for investigator information
Principal Investigator: Antonio Columbo, MD San Raffaele hospital, Milano
Principal Investigator: Giuseppe M Sangiorgi, MD University Hospital Modena Italy
Additional Information:
Layout table for additonal information
Responsible Party: Dr Giuseppe Sangiorgi Dr Antonio Colombo, University Hospital Modena - Italy ; Raffaele hospital, Milano- Italy Identifier: NCT00914420    
Other Study ID Numbers: CST10
First Posted: June 5, 2009    Key Record Dates
Last Update Posted: April 19, 2010
Last Verified: April 2010
Keywords provided by Clearstream Technologies Ltd.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Artery Disease
Acute Coronary Syndrome
Pathologic Processes
Coronary Disease
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Vasodilator Agents